MXPA02001754A - Sistema de ensayo in vitro de gama-secretasa. - Google Patents

Sistema de ensayo in vitro de gama-secretasa.

Info

Publication number
MXPA02001754A
MXPA02001754A MXPA02001754A MXPA02001754A MXPA02001754A MX PA02001754 A MXPA02001754 A MX PA02001754A MX PA02001754 A MXPA02001754 A MX PA02001754A MX PA02001754 A MXPA02001754 A MX PA02001754A MX PA02001754 A MXPA02001754 A MX PA02001754A
Authority
MX
Mexico
Prior art keywords
secretase
membranes
substrate
cells
test kit
Prior art date
Application number
MXPA02001754A
Other languages
English (en)
Spanish (es)
Inventor
Fechteler Katja
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MXPA02001754A publication Critical patent/MXPA02001754A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MXPA02001754A 1999-08-28 2000-08-25 Sistema de ensayo in vitro de gama-secretasa. MXPA02001754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999141039 DE19941039A1 (de) 1999-08-28 1999-08-28 gamma-Sekretase in vitro Testsystem
PCT/EP2000/008340 WO2001016355A2 (de) 1999-08-28 2000-08-25 In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen

Publications (1)

Publication Number Publication Date
MXPA02001754A true MXPA02001754A (es) 2002-10-23

Family

ID=7920037

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001754A MXPA02001754A (es) 1999-08-28 2000-08-25 Sistema de ensayo in vitro de gama-secretasa.

Country Status (6)

Country Link
EP (1) EP1212454A2 (de)
JP (1) JP2003508058A (de)
CA (1) CA2381952A1 (de)
DE (1) DE19941039A1 (de)
MX (1) MXPA02001754A (de)
WO (1) WO2001016355A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10000161A1 (de) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Verfahren zur Identifikation eines Proteaseinhibitors
JP2004505608A (ja) 2000-04-03 2004-02-26 ブリストル−マイヤーズ　スクイブ　カンパニー 機能的に活性なガンマ−セクレターゼタンパク質複合体の単離およびその活性およびインヒビターの検出法
DE60123074T3 (de) 2000-05-11 2015-01-29 Scios Inc. Modulation von gamma-secretase aktivität
DE10131899A1 (de) * 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
WO2005031363A1 (en) * 2003-09-24 2005-04-07 University Of Chicago Membrane preparation from pichia pastoris to assay ϝ-secretase activity
CN1934251A (zh) * 2004-01-29 2007-03-21 塞尔卓姆股份公司 使用atp7a－调控剂治疗神经变性疾病
DE602004011400T2 (de) * 2004-01-29 2009-01-22 Cellzome Ag Behandlung von neurodegenerativen krankheiten mit gpr49

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040885A2 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
CA2191924A1 (en) * 1995-12-05 1997-06-06 Kevin Felsenstein 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of .beta.-amyloid protein production
US6803188B1 (en) * 1996-01-31 2004-10-12 The Regents Of The University Of California Tandem fluorescent protein constructs
GB9608657D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel treatment
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
AU4589297A (en) * 1996-10-07 1998-05-05 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
WO1998021589A1 (en) * 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing

Also Published As

Publication number Publication date
EP1212454A2 (de) 2002-06-12
WO2001016355A2 (de) 2001-03-08
CA2381952A1 (en) 2001-03-08
WO2001016355A3 (de) 2001-08-30
DE19941039A1 (de) 2001-03-01
JP2003508058A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
Baulac et al. Functional γ-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and γ-secretase substrates
Massey et al. Overexpression of ubiquilin decreases ubiquitination and degradation of presenilin proteins
Eikenes et al. ALIX and ESCRT-III coordinately control cytokinetic abscission during germline stem cell division in vivo
EP2272955B1 (de) Tdp-43-speicherzellmodell
Siman et al. Localization of presenilin–nicastrin complexes and γ‐secretase activity to the trans‐Golgi network
JP6166534B2 (ja) 新規調節タンパク質および阻害剤
Laudon et al. Co‐expressed presenilin 1 NTF and CTF form functional γ‐secretase complexes in cells devoid of full‐length protein
Jung et al. Dual‐specificity phosphatase 26 (DUSP 26) stimulates Aβ42 generation by promoting amyloid precursor protein axonal transport during hypoxia
Hoeing et al. Presenilin-1 processing of ErbB4 in fetal type II cells is necessary for control of fetal lung maturation
MXPA02001754A (es) Sistema de ensayo in vitro de gama-secretasa.
Beyer et al. Engulfment adapter PTB domain containing 1 interacts with and affects processing of the amyloid-β precursor protein
Schnöder et al. P38α‐MAPK phosphorylates Snapin and reduces Snapin‐mediated BACE1 transportation in APP‐transgenic mice
Ghersi et al. The intracellular localization of amyloid β protein precursor (AβPP) intracellular domain associated protein-1 (AIDA-1) is regulated by AβPP and alternative splicing
Yin et al. Rootletin prevents Cep68 from VHL-mediated proteasomal degradation to maintain centrosome cohesion
US20020025508A1 (en) Process for finding a protease inhibitor
KR20010080411A (ko) 저산소증-유도성 인자 1α ＨＩＦ-1α 변이체 및ＨＩＦ-1α 조절제의 동정 방법
Yoo et al. NIP1/XB51/NECAB3 is a potential substrate of Nek2, suggesting specific roles of Nek2 in Golgi
Gamliel et al. Increased expression of presenilin 2 inhibits protein synthesis
Jang Intermolecular association between caspase-mediated cleavage fragments of phospholipase D1 protects against apoptosis
Dong et al. A polybasic domain in aPKC mediates Par-6-dependent control of plasma membrane targeting and kinase activity
US7625711B2 (en) Screening method for the identification of a drug for the development of an agent for prevention and/or treatment of Alzheimer's disease
KR100818752B1 (ko) 인간 ｆａｆ1 단백질 억제제를 유효성분으로 함유하는허혈성 질환 치료용 조성물
Hannaford Establishing and Maintaining Cortical Asymmetry in Drosophila Neural Stem Cells
Young et al. β-catenin/Tcf activation partially mimics the transforming activity of Wnt-1 in Rat-1 fibroblasts
US7402406B2 (en) Methods of evaluating phosphatase inhibitors